ライフサイエンスコーパス: anaemia

1 nly used virulence metrics for malaria (e.g. anaemia).

2 red with 53.2% (52.9-53.5) of women with any anaemia.

3 gus macaques experienced only mild/ moderate anaemia.

4 ia but increased the risk of severe malarial anaemia.

5 o HIV have a high prevalence of stunting and anaemia.

6 d reduced the prevalence of parasitaemia and anaemia.

7 , including 5 with a grade 3 or 4 event, all anaemia.

8 idual-level and district-level predictors of anaemia.

9 in clinical use, for the treatment of renal anaemia.

10 tomatic, with no evidence of iron deficiency anaemia.

11 ebral malaria and death from severe malarial anaemia.

12 asound findings in patients with sickle cell anaemia.

13 nd ineffective correction of iron-deficiency anaemia.

14 malaria while 1001 (10%) were severe malaria anaemia.

15 y abnormalities in patients with sickle cell anaemia.

16 cers of autoantibodies that promote malarial anaemia.

17 , but with increased risk of severe malarial anaemia.

18 inability to estimate the cumulative risk of anaemia.

19 y tissues, which leads to toxicities such as anaemia.

20 ce (risk ratio [RR] 0.27, 95% CI 0.17-0.44), anaemia (0.77, 0.65-0.91), and clinical malaria (0.40, 0

21 ansfusion when administered to patients with anaemia 10-42 days before elective major abdominal surge

22 se events that occurred through week 24 were anaemia (10 [5%]), cardiac failure (5 [2%]), pyrexia (4

23 w (17 [3%], pain in extremity (12 [2%]), and anaemia (11 [2%]).

24 1%] of 44 patients), neutropenia (13 [30%]), anaemia (11 [25%]), leukopenia (seven [16%]), febrile ne

25 nia (12 [31%]), thrombocytopenia (13 [33%]), anaemia (11 [28%]), anorexia (nine [23%]), and oral muco

26 adverse events were neutropenia (13 [10%]), anaemia (11 [9%]), and pneumonia (six [5%]).

27 worse treatment-emergent adverse events were anaemia (113 [24%] of 463 patients) and thrombocytopenia

28 olumab group), the most common of which were anaemia (12 [23%] in the pembrolizumab group and 16 [28%

29 e treatment-emergent adverse events included anaemia (13 [30%]) and decreases in neutrophil (nine [20

30 65 [28%] of 232 in the chemotherapy group), anaemia (138 [29%] vs 47 [20%]), and decreased neutrophi

31 common grade 3 or worse adverse events were anaemia (14 [14%] of 104 in the momelotinib group vs sev

32 (57%) of 82 patients, the most common being anaemia (14 [17%]); there were no treatment-related deat

33 lycaemia (17 [22%] of 76 vs two [3%] of 78), anaemia (14 [18%] vs nine [12%]), neutropenia (13 [17%]

34 enia (21 [100%] patients for each toxicity); anaemia (14 [67%] patients); and infection (six [29%] pa

35 [84%] of 171 patients in the control group), anaemia (142 [42%] vs 68 [40%]), and thrombocytopenia (1

36 of 128 patients in the surgery alone group), anaemia (15 [12%] vs ten [8%]), and hypoalbuminaemia (15

37 18 [35%]), pneumonia (15 [29%] vs 19 [37%]), anaemia (15 [29%] vs 12 [23%]), and sepsis (eight [16%]

38 grade 3-4 adverse event in both cohorts was anaemia (15 [31%] of 49 patients in the 300 mg cohort an

39 n both groups were haematological, including anaemia (150 [48%] of 313 patients in the doxorubicin pl

40 82%] of 33), thrombocytopenia (18 [55%]) and anaemia (17 [52%]) in group 2; and neutropenia (23 [66%]

41 16 studies reported on management of anaemia, 17 on dialysis frequency, eight on dialysis acc

42 e treatment-emergent adverse events included anaemia (19 [17%] of 115) and decreased neutrophil (16 [

43 hrombocytopenia (19 [20%] and 33 [33%]), and anaemia (19 [20%] and 25 [25%]); 38 (40%) of 95 patients

44 The most common grade 3-4 adverse event was anaemia (19 [22%] patients).

45 rtate aminotransferase levels (22 [5%]), and anaemia (19 [4%]).

46 such as haemochromatosis, or iron limitation anaemias(2).

47 ]) compared with neutropenia (43 [39%]), and anaemia (20 [18%]), in the taxane group.

48 ommon treatment-emergent adverse events were anaemia (22 [73%] of 34), neutropenia (21 [70%]), and th

49 roup), neutropaenia (21 [40%] and 25 [51%]), anaemia (25 [47%] and 24 [49%]), febrile neutropaenia (1

50 f 91 patients), thrombocytopenia (26 [29%]), anaemia (26 [29%]), decreased white blood cell count (17

51 ]), thrombocytopenia (28 [15%] vs 29 [30%]), anaemia (28 [15%] vs 14 [15%]), and diarrhoea (28 [15%]

52 bumin (33 [10%]), weight loss (29 [9%]), and anaemia (28 [9%]), occurring at similar frequency across

53 vs 16 [20%] of 81 in the combination group), anaemia (3 [4%] vs 19 [23%]), neutropenia (3 [4%] vs 13

54 sone group), fatigue (26 [13%] vs two [1%]), anaemia (31 [16%] vs 20 [10%]), and pneumonia (22 [11%]

55 e neutropenia (40 [28%] of 141 patients) and anaemia (32 [23%]).

56 ost common grade 3 and 4 adverse events were anaemia (34 [13%] of 260 patients evaluable for safety i

57 atients in the platinum-etoposide group) and anaemia (34 [13%], 24 [9%], and 48 [18%]).

58 The most common overall toxicity was anaemia (35 [47%] of 75 patients; five patients had grad

59 f 298 patients vs 97 [32%] of 299 patients), anaemia (37 [12%] vs 43 [14%]), and fatigue (30 [10%] vs

60 Common grade 3-4 adverse events included anaemia (37 [38%] of 97 patients) and thrombocytopenia (

61 rse events of grade 3 or worse severity were anaemia (38 [19%] of 195 patients in the olaparib group

62 up vs 85 [27%] of 315 in the placebo group), anaemia (39 [12%] vs 44 [14%]), and hypertension (32 [10

63 s), thrombocytopenia (72 [7%] patients), and anaemia (42 [4%] patients).

64 and pneumonia (4 [2%]) with pacritinib, and anaemia (5 [5%]), sepsis (2 [2%]), and dyspnoea (2 [2%])

65 uzumab emtansine 2.4 mg/kg weekly group were anaemia (59 [26%]) and thrombocytopenia (25 [11%]) compa

66 mon were osteonecrosis of the jaw (17 [3%]), anaemia (6 [1%]), bone giant cell tumour (6 [1%]), and b

67 were febrile neutropenia (97 [39%] of 252), anaemia (61 [24%]), thrombocytopenia (33 [13%]), sepsis

68 ] of 175 patients), vomiting (63 [36%]), and anaemia (62 [35%]) in the chemotherapy group.

69 openia (70 [22%] of 315 vs 61 [20%] of 312), anaemia (68 [22%] vs 49 [16%]), fatigue (23 [7%] vs 18 [

70 or worse adverse events in both groups were anaemia (7 [15%] of 48 vs 9 [18%] of 49) and thrombocyto

71 (trebananib 238 [35%] vs placebo 126 [38%]) anaemia (76 [11%] vs 40 [12%]), and leucopenia (81 [12%]

72 requent grade 3 or worse adverse events were anaemia (76 [16%] of 463 patients in the carfilzomib gro

73 the overall safety-evaluable population) and anaemia (8 [12%] and 16 [5%]).

74 s), thrombocytopenia (19 [7%] patients), and anaemia (8 [3%] patients).

75 R-pola (most common were neutropenia [23%], anaemia [8%] and diarrhoea [8%]; no grade 5 adverse even

76 se events were diarrhoea (92 [37%] of 252]), anaemia (86 [34%]), fatigue (83 [33%]), elevated asparta

77 These proteins are mutated in Fanconi anaemia, a disease in which patients are predisposed to

78 he remaining three cases was iron deficiency anaemia, abdominal pain and acute intestinal obstruction

79 Fluid retention and anaemia adverse events, which have been previously attri

80 Preoperative anaemia affects a high proportion of patients undergoing

81 district-level and state-level prevalence of anaemia among men correlated strongly with that among wo

82 ween men and women, future efforts to reduce anaemia among men could target similar population groups

83 Anaemia among men in India is an important public health

84 imed to determine the national prevalence of anaemia among men in India; how the prevalence of anaemi

85 iodemographic variation in the prevalence of anaemia among men is similar to that among women to info

86 those targeted in existing efforts to reduce anaemia among women.

87 mean absolute error of 0.73 (0.68-0.78) and anaemia an AUC of 0.89 (0.85-0.93).

88 on serum hepcidin and parameters related to anaemia and CKD-MBD among haemodialysis patients.

89 iesis and lymphopoiesis, leading to frequent anaemia and decreased adaptive immunity.

90 th leukocytosis, lactic acidosis, haemolytic anaemia and hyperbilirubinemia.

91 , and lymphopenia (all for patient number 2; anaemia and lymphopenia were dose-limiting toxicities);

92 Anaemia and malaria are both common in pregnant women in

93 countries are unlikely to reduce stunting or anaemia and might not reduce diarrhoea.

94 common adverse event (ten [11%] events), and anaemia and neutropenia or febrile neutropenia were the

95 The prevalence of anaemia and parasitaemia was measured in a survey at the

96 ated liver cirrhosis was admitted with acute anaemia and recurrence of ascites.

97 e novel therapeutic targets for treatment of anaemia and states of FGF23 excess, including chronic ki

98 to the invasiveness of diagnostic tests for anaemia and the costs associated with screening for it,

99 Either we do not treat anaemia and the patient suffers from chronic tiredness a

100 litinib; one patient (1%) reported grade 3-4 anaemia and three patients (4%) reported grade 3-4 throm

101 arian diet, meaning non-haem iron deficiency anaemia and zinc deficiency immune malfunction are a ris

102 bsorption of iron, vitamin B(12) (pernicious anaemia) and potentially other micronutrients.

103 cco smoking, binge drinking, overweight, and anaemia); and social determinants of health (adolescent

104 convulsions, 1,057/2,340 (45.2%) with severe anaemia, and 441/2,239 (19.7%) with severe respiratory d

105 vents (cryptococcal meningitis, asymptomatic anaemia, and asymptomatic neutropenia) were considered r

106 low birthweight, mild and moderate maternal anaemia, and clinical malaria infection, associated with

107 low birthweight, moderate or severe maternal anaemia, and clinical malaria were calculated from trial

108 rious adverse events were: thrombocytopenia, anaemia, and lymphopenia (all for patient number 2; anae

109 ntries, the value of preoperative testing of anaemia, and methods of optimising haemoglobin concentra

110 h as clinical malaria, maternal and neonatal anaemia, and miscarriage, all of which increase the over

111 ificantly decreases P falciparum prevalence, anaemia, and risk of subsequent clinical malaria across

112 No patient discontinued therapy because of anaemia, and three discontinued because of moderate neut

113 : aOR 0.85, 95% CI 0.80-0.90, p < 0.001; any anaemia: aOR 0.87, 95% CI 0.82-0.92, p < 0.001; severe a

114 OR 0.87, 95% CI 0.82-0.92, p < 0.001; severe anaemia: aOR 0.89, 95% CI 0.84-0.95, p < 0.001).

115 ; p<0.0001; 15 648 individuals; 11 studies), anaemia (ARR 0.85, 0.77-0.92; p<0.0001; 15 026 individua

116 phropathy, chronic kidney disease (CKD), and anaemia as predictors of all-cause mortality.

117 el therapeutic approach for the treatment of anaemia associated with lower-risk myelodysplastic syndr

118 ects (29.3% of Asian females) presented with anaemia, associated with decreased RBCs volume (MCV) and

119 recruited adult participants identified with anaemia at preoperative hospital visits before elective

120 (C=calcium elevation; R=renal impairment; A=anaemia; B=bone involvement) criteria with measurable di

121 ness in cases of severe malaria, with severe anaemia being more insidious than cerebral malaria.

122 ographical and sociodemographic variation of anaemia between men and women, future efforts to reduce

123 n provided a benefit on YLDs associated with anaemia, but these gains were attenuated and sometimes r

124 Here, we show that anaemia can be detected via machine-learning algorithms

125 ergoing regular retinal imaging and for whom anaemia can increase morbidity and mortality risks.

126 predictors of 1-year mortality were old age, anaemia, chronic kidney disease, presence of valvular he

127 on prevalence of P falciparum infection and anaemia, clinical malaria, and cognitive function.

128 e point mutation responsible for sickle cell anaemia codes for a variant hemoglobin, sickle hemoglobi

129 any degree of anaemia had moderate or severe anaemia compared with 53.2% (52.9-53.5) of women with an

130 effective erythropoiesis, chronic haemolytic anaemia, compensatory haemopoietic expansion, hypercoagu

131 and-treat approach to combat iron-deficiency anaemia could achieve equivalent efficacy to universal a

132 Diamond Blackfan anaemia (DBA) is a congenital bone marrow failure syndro

133 of a 34-year-old woman with Diamond-Blackfan anaemia (DBA).

134 (three [7%]) in the bone sarcoma group, and anaemia, decreased lymphocyte count, and prolonged activ

135 ildren aged 2 months to 12 years with severe anaemia, defined as haemoglobin of less than 6 g/dL, at

136 tious diseases, nutritional deficiencies and anaemia, diabetes, and cardiovascular disease in the bla

137 Grade 3-4 anaemia did not differ between groups (8.1% vs 8.3%, p=0

138 DNA damage response network and two Fanconi anaemia DNA repair pathway members showed elevated expre

139 nd efficacy of luspatercept in patients with anaemia due to lower-risk myelodysplastic syndromes.

140 Complications include anaemia due to reduced production of erythropoietin by t

141 of any of these signals ameliorates malarial anaemia during infection in a mouse model.

142 across parasite genotypes or the severity of anaemia each parasite genotype causes.

143 roup compared with in the placebo group were anaemia (eight [4%] of 207 vs five [5%] of 102 patients)

144 The most common serious adverse events were anaemia (eight [4%]), upper gastrointestinal haemorrhage

145 rse were fatigue (14 [10%] of 147 patients), anaemia (eight [5%]), abdominal pain (six [4%]), hypokal

146 ng treatment: two (17%) patients experienced anaemia, eight (67%) neutropenia, and ten (83%) thromboc

147 Severe anaemia, elevated lactate concentration, respiratory dis

148 Repeated sickling and ongoing haemolytic anaemia, even when subclinical, lead to parenchymal inju

149 8 for the crossover population), though most anaemia events were mild to moderate in severity (grade

150 Additionally, blood transfusions to correct anaemia exposes children to safety issues.

151 The Fanconi anaemia (FA) pathway repairs DNA damage caused by endoge

152 k repair, which when impaired causes Fanconi anaemia (FA), a disease resulting in failure to produce

153 Fanconi anaemia (FA), ataxia telangiectasia (A-T), Nijmegen brea

154 of pregnancy, maternal conditions including anaemia, fever during labour, and hypertension accounted

155 group), hypertension (20 [7%] vs two [2%]), anaemia (five [2%] vs six [5%]), and neutropenia (two [1

156 ectrolytes (six [16%] patients), and grade 3 anaemia (four [11%] patients).

157 dverse events, of which the most common were anaemia (four [12%]), neutropenia (three [9%]), and panc

158 3 or 4 treatment-related adverse events were anaemia (four [2%]) in the nivolumab group and decreased

159 ] of 18 patients), lymphopenia (five [28%]), anaemia (four [22%], and thrombocytopenia in three [17%]

160 (four [25%]), thrombocytopenia (four [25%]), anaemia (four [25%]), fever and infection (four [25%]),

161 The most common adverse events were anaemia (four [3%] vs two [4%]) and ARDS (four [3%] vs t

162 de 3-4 treatment-related adverse events were anaemia (four [4%]) and infusion-related reactions (thre

163 se treatment-related adverse events included anaemia (four [6%]) and weight loss (two [3%]).

164 7%) of 1879, and the number of children with anaemia from 245 (13.9%) of 1759 to 193 (10.5%) of 1845.

165 terventions are urgently required for severe anaemia, given the burden it places on overstretched hea

166 eatment-emergent adverse events (TEAEs) were anaemia (grade 3, 26 [18%] of 148 patients; no grade 4 e

167 21.7% (20.9-22.5) of men with any degree of anaemia had moderate or severe anaemia compared with 53.

168 , or visible haematoma; 11 patients had also anaemia (haemoglobin < 7 g/dl).

169 le sex, being ART experienced, having severe anaemia (haemoglobin < 80 g/l), being unable to walk una

170 Anaemia (haemoglobin <11 g/dL) in late pregnancy was neg

171 ate/severe undernutrition or moderate/severe anaemia (haemoglobin <11 g/dL)).

172 ell disease (SCD), including vaso-occlusion, anaemia, haemolysis, organ injury and pain.

173 eived primaquine developed moderately severe anaemia (Hb < 8 g/dL).

174 His mother has Sickle cell anaemia (Hb SS) and his father is a carrier of heterozyg

175 identified 51 (1%) children with sickle cell anaemia (HbSS), four (<1%) heterozygous for HbS and HbC

176 d a CRVO secondary to severe iron-deficiency anaemia (IDA) attributable to menstrual losses and limit

177 Iron deficiency anaemia (IDA) is a common nutritional disorder worldwide

178 follow-up, 25 (46%) of 58 patients had mild anaemia (ie, not requiring intervention), 22 (45%) had h

179 se events were recorded in 2 of 15 patients (anaemia in 1 patient; pneumonia in 1 patient); all arose

180 ents were neutropenia in 161 (60%) patients, anaemia in 101 (37%), and thrombocytopenia in 72 (27%).

181 nced grade 3-5 adverse events, most commonly anaemia in 14 (9%) patients and decreased lymphocyte cou

182 th 1990, and the 430.7 million (24%) who had anaemia in 2016, an increase of 74.2 million compared wi

183 (74%) patients, neutropenia in 53 (62%), and anaemia in 41 (49%).

184 of beta-globin is the primary mechanism for anaemia in beta-thalassaemia.

185 s (ARIs), stunting, wasting, underweight, or anaemia in children aged 0-5 years.

186 Acute anaemia in decompensated liver cirrhosis is commonly cau

187 d young child feeding (IYCF) on stunting and anaemia in in Zimbabwe.

188 Population-based studies on anaemia in India have mostly focused on women and childr

189 cyte age and dose-dependent acute haemolytic anaemia in individuals with glucose-6-phosphate dehydrog

190 tolerated and effective for the treatment of anaemia in lower-risk myelodysplastic syndromes and so c

191 State-level prevalence of any anaemia in men varied from 9.2% (7.7-10.9) in Manipur to

192 ia among men in India; how the prevalence of anaemia in men varies across India among states and dist

193 all associated with a higher probability of anaemia in men.

194 ncreased from 55% to 70%, high prevalence of anaemia in pregnancy decreased from 27% to 11% and high

195 e suggests that low maternal iron status and anaemia in pregnancy may increase the risk of childhood

196 ltivariate regression, gender inequality and anaemia in pregnancy were significantly associated with

197 ive factors including birth weight, maternal anaemia in pregnancy, and socioeconomic factors.

198 oeconomic status) and risk factors (maternal anaemia in pregnancy, depression or lifetime intimate pa

199 Overall, severe anaemia in rhesus macaques infected with P. coatneyi has

200 means of reducing P falciparum infection and anaemia in school-aged children and lowering parasite tr

201 rmalities in adult patients with sickle cell anaemia in steady state attending the Haematology clinic

202 lymphocyte count in three (2%) patients and anaemia in two (1%) patients.

203 ders (MNPs) is a key intervention to prevent anaemia in young children in low-income and middle-incom

204 y) were haematological abnormalities-namely, anaemia (in nine [9%] patients), leucopenia (30 [29%]),

205 verse event of grade 3 or worse severity was anaemia (in six [12%] patients) and no grade 5 adverse e

206 ng those with sickle cell disease was severe anaemia (incidence 48 per 1000 person-years of observati

207 Severe anaemia is a leading cause of paediatric admission to ho

208 In this Review, we consider why paediatric anaemia is a major public health issue in low-income and

209 Anaemia is an important factor to consider preoperativel

210 These data suggest that moderate anaemia is associated with a reduced risk of death in se

211 hest where prevalence of moderate and severe anaemia is greatest but infection prevalence is smallest

212 Prevalence of anaemia is high among children in low-income and middle-

213 Therefore, where anaemia is known to be prevalent and resources are scarc

214 Genetic anaemias lead us to reflect on the classic 'trolley dile

215 (YLDs), and years of life lost (YLLs) due to anaemia, malaria, and diarrhoea averted (or increased) b

216 olled trial to evaluate the effects of FC on anaemia management in haemodialysis patients with hyperp

217 erventions is unlikely to reduce stunting or anaemia more than implementation of IYCF alone.

218 oea (n=11 [5%]) in the pacritinib group, and anaemia (n=16 [15%]), thrombocytopenia (n=12 [11%]), dys

219 Grade 3 adverse events were anaemia (n=2), fatigue (n=1), rash (n=1), and hypothyroi

220 During phase I, grade 3 adverse events were anaemia (n=2), fatigue (n=1), thrombocytopenia (n=1), hy

221 thrombocytopenia (n=58), neutropenia (n=31), anaemia (n=28), fatigue (n=14), hyponatraemia (n=10), an

222 rade 3-4 adverse events through week 24 were anaemia (n=37 [17%]), thrombocytopenia (n=26 [12%]), and

223 alignant neoplasm progression (10 [5%]), and anaemia (nine [4%]).

224 ars, most studies have focused on pernicious anaemia only, generating confusion between the two entit

225 worse treatment-emergent adverse events were anaemia or decreased haemoglobin (45 [22%] patients), an

226 rgent adverse event of grade 3 or higher was anaemia or decreased haemoglobin (80 [22%] patients in t

227 placebo group, the most common of which were anaemia or decreased haemoglobin concentration (70 [19%]

228 No cases of grade 3-4 anaemia or thrombocytopenia occurred with ruxolitinib; o

229 elofibrosis (with no exclusions for baseline anaemia or thrombocytopenia) were randomly assigned (2:1

230 pital mortality was associated with moderate anaemia (OR 0.87 for a decrease of 10 percentage points

231 th at least one of grade 3 thrombocytopenia, anaemia, or bleeding at grade 3 or worse, with palpable

232 The Fanconi anaemia pathway of ICL repair is activated when a replic

233 is (TLS) complex, a component of the Fanconi anaemia pathway, inhibiting error-prone replicative lesi

234 EIL3 pathway is prioritized over the Fanconi anaemia pathway, which can cause genomic rearrangements.

235 by the p97 ATPase, which enables the Fanconi anaemia pathway.

236 Fanconi anaemia patient mutations in XPF often display substanti

237 ltrasonography of 50 consecutive sickle cell anaemia patients were compared with those of 50 age- and

238 In addition to disaggregating anaemia prevalence (separately in men and women) by stat

239 lowest probability of having anaemia whereas anaemia prevalence among women was similar across age gr

240 sitively correlated with moderate and severe anaemia prevalence in Asia, the Middle East, and Latin A

241 Anaemia prevalence was derived from Demographic and Heal

242 rosslink(1); however, if this fails, Fanconi anaemia proteins incise the phosphodiester backbone that

243 BRCA1, BRCA2 and a subset of Fanconi anaemia proteins protect stalled replication forks from

244 lymphocytic lymphoma; incidence of grade 3-4 anaemia ranged from five (13%) of 40 patients with folli

245 e mild to moderate in severity (grade 1 or 2 anaemia rates per 100 patient-years of exposure were 8.0

246 focused on women and children, with men with anaemia receiving much less attention despite anaemia's

247 pen elective abdominal surgery would correct anaemia, reduce the need for blood transfusions, and imp

248 imilar to that among women to inform whether anaemia reduction efforts for men should be coupled with

249 ume overload resulting from hypertension and anaemia, respectively, activation of the renin-angiotens

250 naemia receiving much less attention despite anaemia's adverse effect on health, wellbeing, and econo

251 (ACS) is a major complication of sickle cell anaemia (SCA) and a leading cause for hospital admission

252 Sickle cell anaemia (SCA) is associated with structural manifestatio

253 e is increased in red cells from sickle cell anaemia (SCA) patients.

254 Automated anaemia screening on the basis of fundus images could pa

255 (26 [53%]), thrombocytopenia (eight [16%]), anaemia (seven [14%]), febrile neutropenia (six [12%]),

256 The most common in the olaparib group were anaemia (seven [4%] patients), abdominal pain (three [2%

257 tate aminotransferase (11 [8%] vs two [3%]), anaemia (seven [5%] vs 0), neutropenia (six [5%] vs thre

258 the strength of the known effect of G6PDd on anaemia, showed that this bias is sufficient to explain

259 Overall, the prevalence of anaemia significantly declined (p < 0.001) between the f

260 neonates; neutropenia (25 [6%] neonates) and anaemia (six [1%]) were most common.

261 requent grade 3 or worse adverse events were anaemia (six [14%]), decreased lymphocyte count (five [1

262 re neutropenia (eight [44%] of 18 patients), anaemia (six [33%]), thrombocytopenia (five [28%]), incr

263 most common serious adverse events included anaemia (six [4%] of 141 patients) and pneumonia (five [

264 inotransferase (eight [3%] of 260 patients), anaemia (six, 2%), and decreased neutrophil count (five

265 eding mite, the northern fowl mite can cause anaemia, slower growth, and decreased egg production of

266 l hospital accessibility for severe malarial anaemia (SMA) and cerebral malaria (CM).

267 predictor of presenting with severe malarial anaemia (SMA) in children, with an OR of 2.79 (95% CI:1.

268 Severe malarial anaemia (SMA) is the most common life-threatening compli

269 falciparum infection detected by microscopy, anaemia (study defined values or haemoglobin less than a

270 on between selected child health indicators- anaemia, stunting and no/incomplete immunization by inte

271 improvement from baseline in FACT-An score, anaemia subscale score, and the EQ-5D-5L were reported a

272 Patients with chronic haemolytic anaemia, such as in thalassaemia, require repeated blood

273 matological adverse events of any grade were anaemia (ten [14%] of 74 in the ruxolitinib group vs two

274 tion group were diarrhoea (20 [11%] of 179), anaemia (ten [6%]), increased blood creatine phosphokina

275 four [4%]), febrile neutropenia (four [4%]), anaemia (three [3%]), and neutropenia (three [3%]) in th

276 adverse events were ascites (four [5%]) and anaemia (three [4%]); the only treatment-related grade 3

277 lated treatment-emergent adverse events were anaemia (three [7%]), fatigue (one [2%]), diarrhoea (one

278 The severe anaemia threshold criteria for a definition of severe fa

279 ), hypertension in three patients (10%), and anaemia, thrombocytopenia, and diarrhoea in two patients

280 Anaemia, thrombocytopenia, neutropenia, oesophagitis, di

281 Apart from anaemia, toxicities with olaparib were low grade and man

282 (three [3%]), neutropenia (three [3%]), and anaemia (two [2%]).

283 82%) had grade 3-4 neutropenia, 19 (10%) had anaemia, two (1%) had thrombocytopenia, and 56 (31%) had

284 evere anaemia was 5.1% (4.9-5.4), and severe anaemia was 0.5% (0.5-0.6).

285 In men, the prevalence of any anaemia was 23.2% (95% CI 22.7-23.7), moderate or severe

286 23.2% (95% CI 22.7-23.7), moderate or severe anaemia was 5.1% (4.9-5.4), and severe anaemia was 0.5%

287 The median time to develop severe anaemia was 7.1 weeks(IQR 4.0-12.9) after treatment init

288 A history of anaemia was a risk factor for GHPs which demonstrated ne

289 nce 10%, 95% CI 2-17); and the prevalence of anaemia was also lower in the IYCF groups (45 [14%] of 3

290 Anaemia was defined as haemoglobin less than 130 g/L for

291 Individual variation in anaemia was likely driven by random variation in parasit

292 ecreased neutrophil count (n=2); and grade 4 anaemia was reported by one patient.

293 Anaemia was the most common adverse event in patients re

294 Anaemia was the most frequent severe adverse event.

295 4 years had the lowest probability of having anaemia whereas anaemia prevalence among women was simil

296 nal failure, thrombocytopenia and haemolytic anaemia which is a condition rarely seen in adults.

297 preceded by diabetes mellitus and microcytic anaemia, which are considered to be early manifestations

298 lar between the treatment groups, except for anaemia, which was seen in 12 (21%) of 58 patients in th

299 Mice expressing H3K36M developed severe anaemia with arrested erythropoiesis, a marked haematopo

300 white blood cell count <13 000/muL), and had anaemia with or without red blood cell transfusion suppo